Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors.

MLA

Stille, Julia K., et al. “Design, Synthesis and in Vitro Evaluation of Novel SARS-CoV-2 3CLpro Covalent Inhibitors.” European Journal of Medicinal Chemistry, vol. 229, Feb. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejmech.2021.114046.

APA

Stille, J. K., Tjutrins, J., Wang, G., Venegas, F. A., Hennecker, C., Rueda, A. M., Sharon, I., Blaine, N., Miron, C. E., Pinus, S., Labarre, A., Plescia, J., Burai Patrascu, M., Zhang, X., Wahba, A. S., Vlaho, D., Huot, M. J., Schmeing, T. M., Mittermaier, A. K., & Moitessier, N. (2022). Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors. European Journal of Medicinal Chemistry, 229, N.PAG. https://doi.org/10.1016/j.ejmech.2021.114046

Chicago

Stille, Julia K., Jevgenijs Tjutrins, Guanyu Wang, Felipe A. Venegas, Christopher Hennecker, Andrés M. Rueda, Itai Sharon, et al. 2022. “Design, Synthesis and in Vitro Evaluation of Novel SARS-CoV-2 3CLpro Covalent Inhibitors.” European Journal of Medicinal Chemistry 229 (February): N.PAG. doi:10.1016/j.ejmech.2021.114046.